August 20, 2018 7:16am

Beyond the jeopardies of clinical trials lately it’s algorithms, complacency and downright obliviousness to risk

When you point one finger, there are three fingers pointing back at you?

 

“Venimus nos emit et vendidit nos rursus” – “We have bought and sold again"

Just like algorithms, rules-are-what-we-make-of-them. The take-away, don’t dwell on what’s happened but, learn the lesson of investing in those who define and meet short-term expectation – SUBSCRIBE!

U.S. stock index futures are climbing

Dow futures are UP +0.23% (+58 points) and NASDAQ futures are UP +0.29 % (+22 points)

 

U.S. stock index futures pushed higher ahead of Monday's open, adding to the gains from international markets.

European markets rally ahead of US-China trade talks;

Asia markets closed higher following a report that Chinese and American negotiators are working to de-escalate the trade dispute between the two countries.

 

Data docket: NONE

 

Henry’omics:

Markets in Europe and Asia posted solid gains, helping support U.S. futures, following positive trade developments between the U.S. and China. A strong session from Wall Street on Friday also gave market sentiment a boost.

 

 

With Q2 earnings season all but, over, trading may continue to be driven by shifting factors as mentioned in the title.

Any uptrend in sector equities could be showing signs of “exhaustion”; historically speaking, this week tends to be quiet in terms of trading volume, as there is limited news after corporate earnings and the lack of economic data.

Investors need to pay attention to the low volume movers … and exaggerated moves as a result of the reduced liquidity!

 

Today’s indications:

  • The iShares Nasdaq Biotechnology (IBB) is NOT indicating in Monday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) is NOT indicating in Monday’s pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) is NOT indicating in Monday’s pre-open;
  • The iShares Russell 2000 (IWM) is indicating a +0.24% UPSIDE in Monday’s pre-open

 

I always want to know what happened PRIOR to what might happen today – it sets a tone of consequence:

  • From Friday’s night’s newsletter: “examine the knowns, unknowns and some probable actions. There are “signposts” that provide early warning of sector “oversights”; remember there are triggers or probabilities to momentum.”
  • The iShares NASDAQ Biotechnology (IBB): Friday was barely up +0.02 % after Thursday’s +0.77%, Wednesday’s -1.56%, Tuesday’s +0.56% and last Monday’s -0.05% for a five session aggregate of -0.26% -  upside needed !
  • Of the 45 companies covered on Friday; 18 downside equities finished in a range of -0.27% (EDIT) to -2.66% (CRSP) while the 24 upside equities oscillated from +0.23% (RARE) to =10.2% (MDXG) with 3 flat closes (CUR, BCLI and STML).

 

Companies in my headlights – It’s your decision; I provide the idea and context:

… Everyone deserves a vacation – trying!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.